No response is a good response.

Many meningiomas harbor inactivating mutations in NF2. Cells deficient in the protein merlin (which is the product of NF2) are susceptible to inhibition of focal adhesion kinase (FAK). In the setting of FAK inhibition, NF2 mutated cells have disruption of their adhesions to the extracellular matrix and other cells. In Alliance 071401, 36 patients with NF2 mutations and recurrent or progressive meningioma were treated with a FAK inhibitor. One patient experienced a partial response while 24 (67%) had stable disease as a best response. At 6 months, the rate of progression free survival was 33%. While this may not exactly be groundbreaking, it was better than the historical control of approximately 15%. | Brastianos, J Clin Oncol 2023